Caso contributivo
"Un cuore in fiamme". Un caso di sindrome di Kawasaki complicata da dilatazioni coronariche severe e necessitante di terapia con anakinra
“A heart on fire” A case of Kawasaki syndrome complicated by severe cononary dilatations that requires anakinra therapy
Giulia Maria Gerosa1, Marialetizia Fantasia1, Giulia Ramponi2, Adriana Cristina Balduzzi3
1Scuola di specializzazione in Pediatria, Università Milano – Bicocca
2SC Pediatria Generale, IRCCS Ospedale “San Gerardo dei Tintori”,
3Dipartimento di Medicina e Chirurgia, Università Milano-Bicocca, Fondazione IRCCS “San Gerardo dei Tintori”, Monza
Gennaio 2026 | DOI: 10.53126/MEBXXIXG005
Contenuto riservato
Per leggere l'articolo è necessario effettuare il login.
Classificazione MeSH
Bibliografia
- Rosati A, Consoli C, Mastrolia MV. Malattia di Kawasaki. La newsletter di SIMYoung 2025.
- De Nardi L, Petrone MI, Benvenuto S, Natoli V, Abu-Rumeileh S, Castaldo B, De Benedetti F. Vasculiti facili e difficili: cosa deve sapere e saper fare un pediatra. Medico e Bambino 2023;42(5):286-98. DOI: 10.53126/MEB42286.
- Benelli E, Carbogno S, Carucci NS, et al. Kawasaki facile e difficile. Medico e Bambino 2017;36(3):155-162.
- Marchesi A, Rigante D, Cimaz R, et al. Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease. Ital J Pediatr 2021;47(1):16. DOI: 10.1186/s13052-021-00962-4.
- Newburger JW, De Ferranti SD, Fulton DR. Cardiovascular sequelae of Kawasaki disease: Management and prognosis. UpToDate.
- Jone P, Tremoulet A, Choueiter N, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Clinical Cardiology. Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association. Circulation 2024;150(23): e481-e500. DOI: 10.1161/CIR.0000000000001295.
- McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017;135(17):e927-e999. DOI: 10.1161/CIR.0000000000000484. Erratum in: Circulation 2019;140(5):e181-e184. DOI: 10.1161/CIR.0000000000000703.
- Maggio MC, Prinzi E, Corsello G. Score predittivo di malattia di Kawasaki refrattaria: dati della Clinica Pediatrica di Palermo. Medico e Bambino pagine elettroniche 2014;17(10).
- Chiang WN, Huang PY, Kuo HC, Huang YH, Chang LS. Evaluation of Formosa score and diagnostic sensitivity and specificity of four Asian risk scores for predicting intravenous immunoglobulin resistance in Kawasaki disease: a bivariate meta-analysis. Front Cardiovasc Med 2023;10:1164530. DOI: 10.3389/fcvm.2023.1164530.
- Maggio MC, Cimaz R, Alaimo A, Comparato C, Di Lisi D, Corsello G. Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings. J Med Case Rep 2019;13(1):104. DOI: 10.1186/s13256-019-2028-5.
- Tremoulet AH. Adjunctive therapies in Kawasaki disease. Int J Rheum Dis 2018;21(1):76-9. DOI: 10.1111/1756-185X.13208.
- Yang J, Jain S, Capparelli EV, et al. Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial. J Pediatr 2022;243:173-180.e8. DOI: 10.1016/j.jpeds.2021.12.035.
- Mastrolia MV, Abbati G, Signorino C, et al. Early anti IL-1 treatment replaces steroids in refractory Kawasaki disease: clinical experience from two case reports. Ther Adv Musculoskelet Dis 2021;13:1759720X211002593. DOI: 10.1177/1759720X211002593.
- Ferrara G, Giani T, Caparello MC, Farella C, Gamalero L, Cimaz R. Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review. Paediatr Drugs 2020;22(6):645-52. DOI: 10.1007/s40272-020-00421-3.
- Kone-Paut I, Cimaz R, Herberg J, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series. Autoimmun Rev 2018;17(8):768-74. DOI: 10.1016/j.autrev.2018.01.024.
- Koné-Paut I, Tellier S, Belot A, et al. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease. Arthritis Rheumatol 2021;73(1):151-61. DOI: 10.1002/art.41481.
- Bossi G, Codazzi AC, Vinci F, et al. Efficacy of Anakinra on Multiple Coronary Arteries Aneurysms in an Infant with Recurrent Kawasaki Disease, Complicated by Macrophage Activation Syndrome. Children (Basel) 2022;9(5):672. DOI: 10.3390/children9050672.
- Hoffman HM, Broderick L. The role of the inflammasome in patients with autoinflammatory diseases. J Allergy Clin Immunol 2016;138(1):3-14. DOI: 10.1016/j.jaci.2016.05.001.
- Galeotti C, Bajolle F, Belot A, et al; collaborators. French national diagnostic and care protocol for Kawasaki disease. Rev Med Interne 2023;44(7):354-80. DOI: 10.1016/j.revmed.2023.06.002.
- Gambacorta A, Buonsenso D, De Rosa G, et al. Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra. Front Pediatr 2020;8:195. DOI: 10.3389/fped.2020.00195.